However, a phase II study in urothelial carcinoma found a tolerable safety profile but no significant objective response (NCT03606174), with 51.2% of patients experienced grade 3 treatment-related adverse events (TRAEs) 3.3% encountered grade 4 TRAEs, and one patient died from cardiac failure.266 The phase III SAPPHIRE trial also failed to show improved survival for sitravatinib plus nivolumab compared to docetaxel in advanced NSCLC (NCT03906071).267 Additional multitargeted AXL inhibitors are in development. The gene discussed is AXL; the disease is non-small cell lung carcinoma.